目的评价贝利木单抗联合标准方案治疗儿童活动性狼疮性肾炎的疗效和安全性。这个单一中心,回顾性队列研究使用2004年12月至2023年2月期间在肾内科住院的新活动性狼疮性肾炎患儿的临床资料.根据患者是否接受贝利木单抗,将患者分为贝利木单抗组或传统治疗组。比较两组的肾脏缓解率和复发率以及糖皮质激素剂量。纳入47名儿童(平均年龄11岁),包括传统治疗和贝利木单抗组的30和17名儿童,分别。belimumab组儿童系统性红斑狼疮疾病活动指数-2000(SLEDAI-2000)评分(23.59±7.78)高于传统治疗组(19.13±6.10)(P=0.035)。两组出现脓尿的频率差异无统计学意义,肉眼血尿,以及24小时蛋白尿水平和估计的肾小球滤过率。贝利木单抗组补体C3/C4较传统治疗组恢复快(P<0.05)。6个月或12个月时肾脏完全缓解率无组间差异(P=0.442,P=0.759)。组间1年复发率无差异(P=0.303)。此外,治疗后6个月和12个月,贝利木单抗的糖皮质激素剂量低于传统治疗组(17.87±6.96mg/dvs.27.33±8.40mg/d,P=0.000;10.00(5.3)mg/dvs.13.75(10.0)mg/d,P=0.007),分别。
结论:在肾脏缓解率相等的情况下,贝利木单抗联合标准传统方案可能促进糖皮质激素的减量,不良事件发生率较低。
背景:•Belimumab被证明是对系统性红斑狼疮(c-SLE)LN具有疗效的辅助治疗。•由于缺乏研究,其在儿童LN中的作用和副作用尚不清楚。
背景:•这种单中心,回顾性队列研究评估了贝利木单抗联合标准方案治疗儿童增殖性LN的疗效和安全性.•Belimumab与标准传统治疗相结合可能会促进糖皮质激素的逐渐减少,同时表现出不良事件的低发生率。
The purpose of this study is to evaluate the efficacy and safety of
belimumab combined with the standard regimen in treating children with active lupus nephritis. This single-center, retrospective cohort study used clinical data of children with newly active lupus nephritis hospitalized in the Department of Nephrology between December 2004 and February 2023. Patients were divided into a
belimumab or traditional treatment group according to whether or not they received
belimumab. Renal remission and recurrence rates and glucocorticoid dose were compared between groups. Forty-seven children (median age 11 years) were enrolled, including 30 and 17 children in the traditional treatment and belimumab groups, respectively. The Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000) score of children in the belimumab group (23.59 ± 7.78) was higher than that in the traditional treatment group (19.13 ± 6.10) (P = 0.035). The two groups showed no significant difference in the frequency of pyuria, gross hematuria, and the levels of 24-h proteinuria and estimated glomerular filtration rate. The complement C3/C4 in the belimumab group recovered faster than that in the traditional treatment group (P < 0.05). There were no between-group differences in the complete renal remission rate at 6 or 12 months (P = 0.442, P = 0.759). There were no between-group differences in 1-year recurrence rate (P = 0.303). Furthermore, 6 and 12 months after treatment, glucocorticoid doses were lower in the belimumab than the traditional treatment group (17.87 ± 6.96 mg/d vs. 27.33 ± 8.40 mg/d, P = 0.000; 10.00 (5.3) mg/d vs. 13.75 (10.0) mg/d, P = 0.007), respectively.
CONCLUSIONS: With an equivalent renal remission rate,
belimumab combined with the standard traditional regimen might promote the tapering of glucocorticoids, and the incidence of adverse events is low.
BACKGROUND: • Belimumab is documented as an adjunctive treatment with systemic lupus erythematosus (c-SLE) LN with efficacy. • Due to the paucity of studies, its effects and side effects in children with LN remain unclear.
BACKGROUND: • This single-center, retrospective cohort study evaluated the efficacy and safety of belimumab combined with the standard regimen in treating children with proliferative LN. •
Belimumab combined with the standard traditional treatment might promote the tapering of glucocorticoids, while exhibiting a low occurrence of adverse events.